Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/180396
Title: Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Author: Bastard, Paul
Danish Blood Donor Study
Danish CHGE
Rigo Bonnin, Raúl
HGID Lab University of Hong Kong
Amsterdam UMC Covid-19 Biobank Investigators
St. James’s Hospital SARS CoV2 Interest group
Planas Obradors, Anna M.
CONSTANCES Cohort
COVID Human Genetic Effort
Solanich, Xavier
3C-Dijon Study
Milieu Intérieur Consortium
Cerba HealthCare
Morandeira-Rego, Francisco
Etablissement du Sang study group
NIAID Immune Response To Covid Group
COVID-STORM Clinicians University of Hong Kong
NH-COVAIR Study Group
Pujol Onofre, Aurora
French COVID Cohort Study Group
CoV-Contact Cohort
Imagine COVID Group
Casasnovas Pons, Carlos
Jordan Garcia, Iolanda
Keywords: COVID-19
Immunoglobulines
COVID-19
Immunoglobulins
Issue Date: 19-Aug-2021
Publisher: American Association for the Advancement of Science (AAAS)
Abstract: Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases.
Note: Reproducció del document publicat a: https://doi.org/10.1126/sciimmunol.abl4340
It is part of: Science Immunology, 2021, vol. 6, num. 62
URI: http://hdl.handle.net/2445/180396
Related resource: https://doi.org/10.1126/sciimmunol.abl4340
ISSN: 2470-9468
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
Publicacions de projectes de recerca finançats per la UE
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
sciimmunol.abl4340.pdf4.43 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons